Oxford Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Oxford Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-267,384	Closed	-$868K	–	1737
2019 Q4	$868K	Sell	267,384 -191,599	-42%	-$556K	0.02%	951
2019 Q3	$991K	Sell	458,983 -224,627	-33%	-$600K	0.02%	948
2019 Q2	$2.15M	Sell	683,610 -384,068	-36%	-$1.25M	0.05%	613
2019 Q1	$3.97M	Buy	+1,067,678	New	+$3.6M	0.09%	261
2018 Q2	–	Sell	-35,326	Closed	-$104K	–	2077
2018 Q1	$104K	Buy	35,326 +17,522	+98%	+$47.8K	﹤0.01%	1532
2017 Q4	$51K	Sell	17,804 -88,242	-83%	-$271K	﹤0.01%	1558
2017 Q3	$359K	Buy	+106,046	New	+$295K	0.01%	1299

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oxford Asset Management's PDLI Position: Q1 2020 in Review

Oxford Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 267,384 shares — an estimated $868K sold.

Oxford Asset Management first reported a position in PDLI in Q3 2017 and held it in 7 quarters. The position peaked at $3.97M in Q1 2019. 133 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Oxford Asset Management reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 267,384 PDL BioPharma, Inc. shares in Q1 2020, an estimated $868K.
Oxford Asset Management first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 7 quarters.
Oxford Asset Management's PDL BioPharma, Inc. position peaked at $3.97M in Q1 2019.
133 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.